Avdl stock forecast based on Q1 earnings projections

Based on Q1 earnings projections, avdl stock forecast is leaning toward a moderate bullish trend, driven by anticipated revenue growth in its sleep disorder treatment pipeline. Analysts are watching closely for insider buying activity as a confidence indicator. AGB und Datenschutzerklärung Your Privacy Choices CA Privacy Notice More Info Avadel Pharmaceuticals Plc engages in the development and commercialization of pharmaceutical products. Its main product is LUMRYZ is an extended-release formulation of sodium oxybate, which used in the treatment of cataplexy or EDS in adults with narcolepsy. The company was founded on July 21, 1990 and is headquartered in Dublin, Ireland. Earnings-per-share estimates in the avdl stock forecast point toward narrowing losses, a positive metric for valuation models used by growth-oriented analysts.